To highlights the recent trends and challenges in wound care management, Genetix Biotech has recently organised a ‘symposium on wound care’ in which large number of doctors and medical professionals including noted vascular surgeons Dr V S Bedi, Dr. Ambarish Satwik, and eminent plastic surgeon Dr. V.K. Tiwari participated
By Mohd Ujaley
US-based biopharmaceutical company Oculus Innovative Sciences has tied up with India’s Genetix Biotech to expand its footprints in India. As per the agreement, Genetix, which deals in distribution of biotechnology, life sciences and laboratory research products will be the exclusive Indian distributor of Oculus family of Wound Care products called Microdacyn60 Wound Care, said a statement from Genetix Biotech.
The company’s products, which are sold throughout 32 countries, have shown improved outcomes for more than five million patients globally by reducing infections, itch, pain, scarring and harmful inflammatory responses, without any reports of contraindications, claims company.
Company informed that ‘Microdacyn60 Wound Care’ has passed various tests on toxicity, sensitisation and irritation and is literally “Safe as water”; no toxic ingredients, no additives, no surfactants, no other chemicals, absolutely safe and no risk of any accumulation of toxic ingredients over time
‘Microdacyn60 Wound Care’, either available as a hydrogel or liquid, can be used during all stages of the wound and is commonly being use for the treatment of abrasionsand irritations to skin, land 2 degree burns, surgical wounds, pressure ulcers, venous stasis ulcers, diabetic foot ulcers and Traumatic wounds, Oculus stated.
According to Oculus, ‘Microdacyn60 Wound Care’ can be used either as a mono-therapy during irrigation and immersion but also in combination with debridement, positive pressure systems, dressings and gauzes and negative pressure systems. It is also compatible with Skin substitutes, Skin grafts, (Silver) dressings and abdominal meshes.
The technology is supported by more than 30 clinical papers from all around the world, documenting the same consistent safety and efficacy and supporting the body to perform its own healing process, asserts Oculus.
“We are so excited to launch Microdacyn60 Wound Care. Not only because the huge potential because of the product’s great features and benefits but also because this is a perfect fit in our current product portfolio,” said Arun Prakash, CEO of Genetix, adding that company will put all efforts on the positioning and coverage of this product in all over India. “We will create awareness about this product amongst all health care practitioners and are convinced that this is going to be a big success” he added.
To highlights the recent trends and challenges in wound care management, Genetix has also recently organised a ‘symposium on wound care’ in which large number of doctors and medical professionals from across the country participated.
During the symposium, noted vascular surgeons Dr V S Bedi annd Dr. Ambarish Satwik, and eminent plastic surgeon Dr.V.K. Tiwari presented their overview on the various developments happening in the area of wound care management. Also, Bruce Thornton, executive vice president, Oculus Innovative Sciences highlighted on offerings for wound care management from Oculus.
